| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
|
J Clin Oncol
|
2013
|
5.36
|
|
2
|
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
|
J Clin Oncol
|
2005
|
4.77
|
|
3
|
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
|
J Clin Oncol
|
2009
|
2.53
|
|
4
|
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
|
Clin Cancer Res
|
2010
|
2.20
|
|
5
|
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
|
Oncologist
|
2007
|
1.93
|
|
6
|
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
|
Clin Cancer Res
|
2009
|
1.81
|
|
7
|
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
|
J Transl Med
|
2008
|
1.56
|
|
8
|
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
|
Clin Cancer Res
|
2009
|
1.49
|
|
9
|
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
|
Clin Cancer Res
|
2011
|
1.42
|
|
10
|
Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.
|
Clin Cancer Res
|
2006
|
1.37
|
|
11
|
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
|
Cancer
|
2006
|
1.35
|
|
12
|
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
|
J Clin Oncol
|
2010
|
1.24
|
|
13
|
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
|
J Nucl Med
|
2010
|
1.13
|
|
14
|
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.
|
PLoS One
|
2010
|
1.09
|
|
15
|
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
|
J Transl Med
|
2012
|
0.87
|
|
16
|
Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
|
Am J Ophthalmol
|
2007
|
0.86
|
|
17
|
Natural killer T cells in advanced melanoma patients treated with tremelimumab.
|
PLoS One
|
2013
|
0.83
|